Advertisement

Journal of Molecular Neuroscience

, Volume 11, Issue 2, pp 127–134 | Cite as

Molecular mapping of epitopes involved in ligand activation of the human receptor for the neuropeptide, VIP, based on hybrids with the human secretin receptor

  • Björn Olde
  • Alan Sabirsh
  • Christer Owman
Article

Abstract

Receptors for the neurotransmitter and neuroendocrine peptides, vasoactive intesinal peptide (VIP) and secretin, both belong to the Type B subfamily of G-protein-coupled receptors. This group is evolutionally as well as structurally distinct from the much larger Type A, or rhodopsin-type, subfamily. We have mapped the ligand-activating epitopes of the human VIP1 receptor by the use of hybrid receptor constructs with the human secretin receptor. Twelve chimeras were synthesized by successively replacing portions of the former receptor with corresponding portions of the latter receptor, or by interchanging the first extracellular loops. Each of the different chimeric receptor DNAs were then expressed in murine reporter cells, and their ability to activate cAMP production was investigated on stimulation with the respective natural peptide ligands. We stimulated the reporter cells with secretin or VIP following transient expression of the receptor chimeras. The experiments indicated that there are two molecular domains of importance for the recognition and activation of these peptides, namely, the inner portion of the extracellular tail and the first extracellular loop of the two receptors.

Index Entries

Human VIP receptor secretin receptor chimeric receptors ligand activation 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Arimura A. and Said S. S., eds. (1996) VIP, PACAP, and related peptides. Ann. NY Acad. Sci. 805, 1–792.Google Scholar
  2. Beaubien B., Tippins J. R., and Morris H. R. (1984) Platelet-activating factor stimulation of peptidoleukotriene release: inhibition by vasoactive polypeptide. Biochem. Biophys. Res. Com. 125, 105–108.PubMedCrossRefGoogle Scholar
  3. Barik S. and Galinski M. S. (1991) “Megaprimer” method of PCR: increased template concentration improves yield. BioTechniques 10, 489,490.PubMedGoogle Scholar
  4. Bolin D. R., Michalewsky J., Wasserman M. A., and O’Donnel M. (1995) Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 37, 57–66.PubMedCrossRefGoogle Scholar
  5. Buggy J. J., Livingston J. N., Rabin D., and Warren H. Y. (1995) Glucagon, glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding. J. Biol. Chem. 270, 7474–7478.PubMedCrossRefGoogle Scholar
  6. Gether U., Johansen T. E., and Schwartz T. W. (1993) Chimeric NK1 (substance P)/NK3 (neurokinin B) receptors. Identification of domains determining the binding specificity of tachykinin agonists. J. Biol. Chem. 268, 7893–7898.PubMedGoogle Scholar
  7. Gourlet P., Vilardaga J.-P., De Neef P., Waelenbroeck M., Vandemeers A., and Robberecht P. (1996) The C-terminus ends of secretin and VIP interact with the N-terminal domains of their receptors. Peptides 17, 825–829.PubMedCrossRefGoogle Scholar
  8. Hjorth S. A., Adelhorst K., Pedersen Brogaard B., Kirk O., and Schwartz T. (1994) Glucagon and glucagon-like peptide 1: selective receptor recognition via distinct peptide epitopes. J. Biol. Chem. 269, 30,121–30,124.Google Scholar
  9. Holtmann M. H., Hadac E. M., and Miller L. J. (1995) Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. Studies of chimeric receptors. J. Biol. Chem. 270, 14,394–14,398.Google Scholar
  10. Horton R. M., Cai Z., Ho S. N., and Pease L. R. (1990) Gene splicing by overlap extension: tailor-made genes using the polymerase chain reaction. BioTechniques 8, 528–535.PubMedGoogle Scholar
  11. König M., Mahan L. C., Marsh J. W., Fink J. S., and Brownstein M. J. (1991) Method for identifying ligands that bind to cloned Gs- or Gi - coupled receptors. Mol. Cell. Neurosci. 2, 331–337.CrossRefPubMedGoogle Scholar
  12. Lardelli M. and Lendahl U. (1994) Generating bacteriophage lambda sublibraries enriched for rare clones. BioTechniques 16, 420–422.PubMedGoogle Scholar
  13. Lefebre B., Formstecher P., and Lefebre P. (1995) Improvement of the gene splicing overlap (SOE) method. BioTechniques 19, 186–188.Google Scholar
  14. Ollerenshaw S., Jarvis D., Woolcock A., Sullivan C., and Scheibner T. (1989) Absence of immunoreactive intestinal polypeptide in tissue from the lungs of patients with asthma. New Engl. J. Med. 320, 1244–1248.PubMedCrossRefGoogle Scholar
  15. Patel D. P., Kong Y., and Sreedharan S. P. (1995) Molecular cloning and expression of a human secretin receptor. Mol. Pharm. 47, 467–473.Google Scholar
  16. Pont-Kingdon G. (1994) Construction of chimeric molecules by a two-step recombinant PCR method. BioTechniques 16, 1010,1011.PubMedGoogle Scholar
  17. Sarkar G. and Sommer S. S. (1990) The “megaprimer” method of site-directed mutagenesis. BioTechniques 8, 404–407.PubMedGoogle Scholar
  18. Segre G. V. and Goldring S. R. (1993) Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagonlike peptide 1, growth hormone-releasing hormone and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol. Metab. 4, 309–314.CrossRefPubMedGoogle Scholar
  19. Tams J., Knudsen S. M., and Fahrenkrug J. (1998) Proposed arrangement of the seven transmembrane helices in the secretin receptor family. Rec. Channels 5, 79–90.Google Scholar
  20. Trotz M. E. and Said S. L. (1993) Vasoactive intestinal peptide and helodermin inhibit phospholipase A2 activity in vitro. Regul. Pept. 48, 301–307.PubMedCrossRefGoogle Scholar
  21. Vilardaga J-P., De Neef P., Di Paolo E., Bollen A., Waelbroeck M., and Robberecht P. (1995) Properties of chimeric secretin and VIP receptor proteins indicate the importance of the N-terminal domain for ligand discrimination. Biochem. Biophys. Res. Commun. 211, 885–891.PubMedCrossRefGoogle Scholar

Copyright information

© Humana Press Inc 1999

Authors and Affiliations

  • Björn Olde
    • 1
  • Alan Sabirsh
    • 1
  • Christer Owman
    • 1
  1. 1.Section of Molecular Neurobiology, Department of Physiology and Neuroscience, Wallenberg Neuroscience CenterUniversity of LundLundSweden

Personalised recommendations